Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19465330 | 0.91 | LTA4H (0.63) | FKBP1ALTA4HALDH1A1NPSR1KMT2A | |
| SCHEMBL952721 | 0.91 | LTA4H (0.63) | FKBP1ALTA4HALDH1A1NPSR1KMT2A | |
| SCHEMBL952722 | 0.91 | LTA4H (0.63) | FKBP1ALTA4HALDH1A1NPSR1KMT2A | |
| SCHEMBL20312897 | 0.90 | SIGMAR1 (0.51) | FKBP1ALTA4H | |
| SCHEMBL7181767 | 0.90 | MEN1 (0.60) | FKBP1ALTA4HALDH1A1KMT2AMEN1 | |
| SCHEMBL6540812 | 0.90 | MEN1 (0.60) | FKBP1ALTA4HALDH1A1KMT2AMEN1 | |
| SCHEMBL2919874 | 0.88 | CYP3A4 (0.53) | FKBP1ALTA4HALDH1A1NPSR1MAPT | |
| SCHEMBL2919878 | 0.88 | CYP3A4 (0.53) | FKBP1ALTA4HALDH1A1NPSR1MAPT | |
| SCHEMBL2919871 | 0.88 | CYP3A4 (0.53) | FKBP1ALTA4HALDH1A1NPSR1MAPT | |
| SCHEMBL2769632 | 0.87 | CYP3A4 (0.54) | LTA4HALDH1A1CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-07 | — | — | US | disclosed |
| US-6410279-B1 | GENERATING PREFERENTIAL COMPOUND IN SOLUTION; OBTAIN N-SUBSTITUTED AZETIDINE-2-CARBOXYLIC ACID ESTER, INCUBATE WITH PREFERENTIAL ENZYME, RECOVER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1201653-A1 | Method for racemization of optically active azetidine-2-Carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| EP-1181273-A1 | NEW PROCESS | AstraZeneca AB (SE) | 2002-02-27 | — | — | EP | disclosed |
| US-6166224-A | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-26 | — | — | US | disclosed |
| US-6162621-A | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-12-19 | — | — | US | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000068193-A1 | NEW PROCESS | ASTRAZENECA AB (SE) | 2000-11-16 | — | — | WO | disclosed |
| EP-0957089-A1 | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0855446-A2 | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | IMPDH2, INHA, IMPDH1 | FKBP1A 542/4885LTA4H 3520/4885ALDH1A1 2545/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | FKBP1A 2577/4885LTA4H 3802/4885ALDH1A1 3370/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | FKBP1A 2577/4885LTA4H 3802/4885ALDH1A1 3370/4885 |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | IDO1, IDO2, SLC1A2 | FKBP1A 1055/4885LTA4H 483/4885ALDH1A1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.